

Experience in COVID-19 in hospitalized patients in pediatric critical units during pandemic period

Experiencia en COVID-19 en pacientes hospitalizados en unidades de paciente crítico pediátrico durante el periodo pandémico

Supplementary table 1. Comparison between groups of pediatric critical patients who evolved with severe COVID-19 according to alive / dead (n = 58)

Characteristics	Alive (n = 50)	Dead (n = 8)	OR (95% IC)	p-value
Gender male	23 (46)	5 (62.5)	1.9 (0.42-9.1)	0.46
Age (months)	74.5 (25-147.7)	69.5 (3.5-180)		0.85
Comorbidities				
Obesity	19 (38)	2 (25)	0.54 (0.01-2.9)	0.7
Oncological	0 (0)	3 (37.5)		
Respiratory*	7 (14)	3 (37.5)	3.6 (0.7-18.9)	0.13
Immunodeficiency	1 (2.0)	4 (50)	49 (4.3-549)	0.001*
Preterm	2 (4.0)	1 (12.5)	3.4 (0.3-42.9)	0.37
Malnutrition	4 (8.0)	1 (12.5)	1.6 (0.15-16.9)	0.54
Diabetes	2 (4.0)	1 (12.5)	3.4 (0.27-42.9)	0.36
Congenital heart disease	3 (6.0)	1 (12.5)	2.2 (0.2-24.6)	0.46
Others	10 (20)	7 (87.5)		
Contact type with a COVID-19 case				0.96
Within Hospital	4 (8)	1 (12.5)		
Known extra household	1 (2.0)	0 (0)		
Intradomicile	24 (48)	4 (50)		
Unknown	21 (42)	3 (37.5)		
Admission diagnosis				0.13
Pneumonia	18 (36)	3 (37.5)		
Shock	35 (70)	2 (25)		
Myocarditis	3 (6.0)	1 (12.5)		
Encephalitis	0 (0)	1 (12.5)		
Others**	12 (24)	1 (12.5)		
Chest X Ray Pattern				
Atelectasis	2 (4.0)	2 (25)	8 (0.9-67.7)	0.08
Pleural Effusion	2 (4.0)	0 (0)		
Pneumonia	14 (28)	5 (62.5)	4.2 (0.9-20.3)	0.09
Thorax CT				
Atelectasis	2 (4.0)	2 (25)	8 (0.9-67.7)	0.9
Pneumonia	6 (12)	4 (50)	7.3 (1.4-37.3)	0.02*
Pleural effusion	2 (4.0)	0 (0)		
Pneumothorax	2 (4.0)	0 (0)		
Ground glass opacities	6 (12)	3 (37.5)	4.4 (0.83-23.3)	0.9

COVID-19 empirical treatment	0 (0)	1 (12.5)		
Hydroxichloroquine	6 (13.3)	0 (0)		
Azithromycin	0 (0)	0 (0)		
Ivermectin	0 (0)	0 (0)		
Lopinavir/ritonavir	0 (0)	0 (0)		
Remdesivir	0 (0)	0 (0)		
Oseltamivir	0 (0)	0 (0)		
Tocilizumab	0 (0)	0 (0)		
Systemic corticosteroids				
Hydrocortisone	4 (0)	0 (0)		
Methylprednisolone	27 (57.4)	5 (62.5)	1.2 (0.26-5.78)	1.0
Dexamethasone	17 (37.8)	2 (33.3)	0.82 (0.4-4.9)	1.0
Stress dose steroids	9 (18)	6 (75)	13.7 (2.4-79.1)	0.003*
IVIG	27 (57.4)	6 (75)	2.2 (0.4-12.2)	0.45
Heparin	39 (79.6)	5 (71.4)	0.6 (0.1-3.8)	0.64
Antibiotics prescription	49 (98)	8 (100)		
Bronchodilators	8 (16)	3 (37.5)	3.2 (0.6-15.9)	0.17
Vasoactive drugs	38 (76)	8 (100)		
Plasmapheresis	0 (0)	1 (12.5)		
Transfusion				
Red blood cells	13 (27.7)	7 (87.5)	18.3 (2.0-163.7)	0.002*
Fresh frozen plasma	1 (2.2)	0 (0)		
Cryoprecipitate	0 (0)	0 (0)	33 (2.7-395.6)	
Platelets	1 (2.2)	3 (42.9)		0.006*
Coinfection				
Bacterial	12 (24)	4 (50)	3.1 (0.69-14.6)	0.2
Viral	0 (0)	2 (25)		
Fungal	3 (6.0)	4 (50)	15.6 (2.55-95.9)	0.005*

*Significant. Abbreviations: IQR: interquartile range. *Includes: asthma, bronchopulmonary dysplasia, chronic lung damage, bronchial hyperreactivity, cystic fibrosis. **Patients admitted to UCP for another diagnosis in whom SARS-Cov-2 was screened upon admission.